S&P 500   3,784.31 (+2.88%)
DOW   30,268.85 (+2.64%)
QQQ   281.49 (+2.91%)
AAPL   145.68 (+2.27%)
MSFT   247.92 (+2.98%)
META   139.94 (+0.96%)
GOOGL   101.23 (+2.63%)
AMZN   120.76 (+4.21%)
TSLA   247.96 (+2.29%)
NVDA   131.16 (+4.83%)
NIO   16.66 (+7.55%)
BABA   84.03 (+4.45%)
AMD   67.84 (+2.62%)
T   16.04 (+0.88%)
MU   53.87 (+4.16%)
CGC   3.12 (+7.22%)
F   12.29 (+7.15%)
GE   67.19 (+5.64%)
DIS   100.78 (+3.76%)
AMC   7.80 (+13.37%)
PYPL   92.60 (+6.22%)
PFE   44.33 (+0.43%)
NFLX   239.00 (-0.02%)
S&P 500   3,784.31 (+2.88%)
DOW   30,268.85 (+2.64%)
QQQ   281.49 (+2.91%)
AAPL   145.68 (+2.27%)
MSFT   247.92 (+2.98%)
META   139.94 (+0.96%)
GOOGL   101.23 (+2.63%)
AMZN   120.76 (+4.21%)
TSLA   247.96 (+2.29%)
NVDA   131.16 (+4.83%)
NIO   16.66 (+7.55%)
BABA   84.03 (+4.45%)
AMD   67.84 (+2.62%)
T   16.04 (+0.88%)
MU   53.87 (+4.16%)
CGC   3.12 (+7.22%)
F   12.29 (+7.15%)
GE   67.19 (+5.64%)
DIS   100.78 (+3.76%)
AMC   7.80 (+13.37%)
PYPL   92.60 (+6.22%)
PFE   44.33 (+0.43%)
NFLX   239.00 (-0.02%)
S&P 500   3,784.31 (+2.88%)
DOW   30,268.85 (+2.64%)
QQQ   281.49 (+2.91%)
AAPL   145.68 (+2.27%)
MSFT   247.92 (+2.98%)
META   139.94 (+0.96%)
GOOGL   101.23 (+2.63%)
AMZN   120.76 (+4.21%)
TSLA   247.96 (+2.29%)
NVDA   131.16 (+4.83%)
NIO   16.66 (+7.55%)
BABA   84.03 (+4.45%)
AMD   67.84 (+2.62%)
T   16.04 (+0.88%)
MU   53.87 (+4.16%)
CGC   3.12 (+7.22%)
F   12.29 (+7.15%)
GE   67.19 (+5.64%)
DIS   100.78 (+3.76%)
AMC   7.80 (+13.37%)
PYPL   92.60 (+6.22%)
PFE   44.33 (+0.43%)
NFLX   239.00 (-0.02%)
S&P 500   3,784.31 (+2.88%)
DOW   30,268.85 (+2.64%)
QQQ   281.49 (+2.91%)
AAPL   145.68 (+2.27%)
MSFT   247.92 (+2.98%)
META   139.94 (+0.96%)
GOOGL   101.23 (+2.63%)
AMZN   120.76 (+4.21%)
TSLA   247.96 (+2.29%)
NVDA   131.16 (+4.83%)
NIO   16.66 (+7.55%)
BABA   84.03 (+4.45%)
AMD   67.84 (+2.62%)
T   16.04 (+0.88%)
MU   53.87 (+4.16%)
CGC   3.12 (+7.22%)
F   12.29 (+7.15%)
GE   67.19 (+5.64%)
DIS   100.78 (+3.76%)
AMC   7.80 (+13.37%)
PYPL   92.60 (+6.22%)
PFE   44.33 (+0.43%)
NFLX   239.00 (-0.02%)

Gracell Biotechnologies - GRCL News Today

$3.32
+0.05 (+1.53%)
(As of 10/4/2022 03:20 PM ET)
Add
Compare
Today's Range
$3.30
$3.45
50-Day Range
$2.08
$3.86
52-Week Range
$1.68
$15.00
Volume
237 shs
Average Volume
66,267 shs
Market Capitalization
$224.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Get Gracell Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRCL and its competitors with MarketBeat's FREE daily newsletter.



GRCL Media Mentions By Week

GRCL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GRCL
News Sentiment

1.66

0.82

Average
Medical
News Sentiment

GRCL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GRCL Articles
This Week

3

1

GRCL Articles
Average Week

SourceHeadline
investing.com logoGracell Biotechnologies Inc. Misses Q2 EPS by 15c
investing.com - August 16 at 10:25 PM
seekingalpha.com logoGracell Biotechnologies Inc. (GRCL) CEO Dr. William Cao on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 15 at 12:20 PM
finance.yahoo.com logoGracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
finance.yahoo.com - August 15 at 12:20 PM
finance.yahoo.com logoDo Institutions Own Gracell Biotechnologies Inc. (NASDAQ:GRCL) Shares?
finance.yahoo.com - August 8 at 4:22 PM
seekingalpha.com logoGracell Biotechnologies rallies after naming new chief medical officer
seekingalpha.com - August 2 at 10:42 PM
finance.yahoo.com logoGracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022
finance.yahoo.com - August 2 at 12:32 PM
finance.yahoo.com logoGracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer
finance.yahoo.com - August 1 at 10:44 AM
finance.yahoo.com logoGracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
finance.yahoo.com - July 19 at 12:44 PM
seekingalpha.com logoGracell Biotechnologies (GRCL) Presents at the 27th Congress of the European Hematology Association (EHA) - Slideshow
seekingalpha.com - June 21 at 2:10 PM
marketwatch.com logoGracell Biotechnologies Shares Reverse Course, Drop 13% After Study Results
marketwatch.com - June 13 at 6:36 PM
finance.yahoo.com logoGracell Reveals Encouraging Data From Pretreated Multiple Myeloma Patients
finance.yahoo.com - June 13 at 6:36 PM
finance.yahoo.com logoGracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients
finance.yahoo.com - June 12 at 8:46 AM
finance.yahoo.com logoGracell Biotechnologies Schedules Clinical Update Call After EHA2022
finance.yahoo.com - June 3 at 11:20 AM
finance.yahoo.com logoGracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting CAR-T GC012F for Relapsed/Refractory Multiple Myeloma at 2022 ASCO Annual Meeting
finance.yahoo.com - May 26 at 9:43 PM
finance.yahoo.com logoGracell Biotechnologies to Participate in Three Upcoming Investor Conferences
finance.yahoo.com - May 19 at 8:54 AM
seekingalpha.com logoGracell Biotechnologies GAAP EPS of -$0.07 in-line
seekingalpha.com - May 17 at 10:42 PM
seekingalpha.com logoGracell Biotechnologies Inc. (GRCL) CEO Dr. William Cao on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 3:58 PM
finance.yahoo.com logoGracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
finance.yahoo.com - May 16 at 10:58 AM
finance.yahoo.com logoGracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update
finance.yahoo.com - May 16 at 10:58 AM
finance.yahoo.com logoGracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress
finance.yahoo.com - May 12 at 12:43 PM
finance.yahoo.com logoGracell Biotechnologies to Participate in Three Investor Conferences in May
finance.yahoo.com - May 4 at 11:09 AM
finance.yahoo.com logoGracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
finance.yahoo.com - May 2 at 10:47 AM
finance.yahoo.com logoGracell Biotechnologies Announces Details of Oral Abstract Presentation at 2022 ASCO Annual Meeting
finance.yahoo.com - April 28 at 3:17 PM
benzinga.com logoGracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2021
benzinga.com - April 22 at 7:51 PM
finance.yahoo.com logoGracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting
finance.yahoo.com - April 14 at 10:05 AM
finance.yahoo.com logoGracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL
finance.yahoo.com - April 8 at 7:09 PM
finance.yahoo.com logoGracell Biotechnologies to Participate in Three Investor Conferences in April
finance.yahoo.com - March 29 at 8:53 AM
seekingalpha.com logoU.S.-listed Chinese pharma stocks are on the rise
seekingalpha.com - March 16 at 10:46 AM
benzinga.com logoGracell Biotechnologies: Q4 Earnings Insights
benzinga.com - March 14 at 12:18 PM
seekingalpha.com logoGracell Biotechnologies GAAP EPS of -$0.06 beats by $0.10
seekingalpha.com - March 14 at 12:18 PM
finance.yahoo.com logoGracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 12:18 PM
seekingalpha.com logoGracell Biotechnologies Inc. 2021 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 14 at 10:55 AM
morningstar.com logoGracell Biotechnologies Inc ADR GRCL
morningstar.com - March 12 at 10:49 PM
benzinga.com logoGracell Biotechnologies Earnings Preview
benzinga.com - March 12 at 10:49 PM
finance.yahoo.com logoGracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference
finance.yahoo.com - March 10 at 5:28 PM
finance.yahoo.com logoGracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022
finance.yahoo.com - March 8 at 8:27 PM
finance.yahoo.com logoGracell Biotechnologies to Report Fourth Quarter & Full Year 2021 Financial Results on Monday, March 14, 2022
finance.yahoo.com - March 2 at 8:28 AM
finance.yahoo.com logoWhat Type Of Shareholders Own The Most Number of Gracell Biotechnologies Inc. (NASDAQ:GRCL) Shares?
finance.yahoo.com - March 1 at 10:12 PM
finance.yahoo.com logoGracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform
finance.yahoo.com - February 22 at 3:35 PM
finance.yahoo.com logoGracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma
finance.yahoo.com - February 17 at 10:38 AM
finance.yahoo.com logoGracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit
finance.yahoo.com - February 3 at 8:51 AM
finance.yahoo.com logoGracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference
finance.yahoo.com - January 18 at 10:53 AM
nasdaq.com logoGracell Biotechnologies Inc - ADR Shares Approach 52-Week Low - Market Mover
nasdaq.com - December 30 at 9:11 AM
finance.yahoo.com logoGracell Biotechnologies Selected for Addition to NASDAQ Biotechnology Index
finance.yahoo.com - December 16 at 9:11 AM
benzinga.com logoGracell Bio Shares Tumble as Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment
benzinga.com - November 29 at 2:04 PM
finance.yahoo.com logoGracell Biotechnologies Announces Senior Management Team Share Purchase Plan
finance.yahoo.com - November 23 at 1:01 PM
marketwatch.com logoGracell Gets FDA Orphan Designation for GC012F in Multiple Myeloma >GRCL
marketwatch.com - November 19 at 8:52 AM
nasdaq.com logoGracell: GC012F Granted Orphan Drug Designation For Treatment Of Multiple Myeloma
nasdaq.com - November 19 at 8:52 AM
finance.yahoo.com logoGracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
finance.yahoo.com - November 17 at 6:25 PM
finance.yahoo.com logoGracell Biotechnologies Reports Third Quarter 2021 Unaudited Financial Results and Provides Corporate Update
finance.yahoo.com - November 15 at 8:40 AM
Get Gracell Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRCL and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:GRCL) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.